WUXI BIOLOGICS- WILL PROVIDE AN EXCLUSIVE LICENSE TO GSK FOR ONE PRECLINICAL BI-SPECIFIC ANTIBODY AND OPTION OF 3 ADDITIONAL BI-/MULTI-SPECIFIC TCE ANTIBODIES
Wuxi Biologics- Will Provide An Exclusive License To Gsk For One…
![Reuters logo](/images/reuters.jpg)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,534 GBX | +0.39% |
|
+1.85% | +5.69% |
07-17 | European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading | MT |
07-17 | EU court criticizes Commission over handling of COVID vaccine contracts | RE |
WUXI BIOLOGICS- WILL PROVIDE AN EXCLUSIVE LICENSE TO GSK FOR ONE PRECLINICAL BI-SPECIFIC ANTIBODY AND OPTION OF 3 ADDITIONAL BI-/MULTI-SPECIFIC TCE ANTIBODIES
1st Jan change | Capi. | |
---|---|---|
+6.09% | 81.07B | |
+55.35% | 815B | |
+31.99% | 597B | |
-0.10% | 377B | |
+15.47% | 319B | |
+13.10% | 310B | |
+16.18% | 247B | |
+14.08% | 228B | |
+16.54% | 180B | |
+4.31% | 170B |